Successful afatinib rechallenge in a patient with non-small cell lung cancer harboringEGFRG719CandS768Imutations

Recent studies have indicated that afatinib is beneficial for patients with non-small cell lung cancer (NSCLC) harboring uncommonepidermal growth factor receptor(EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long-term survival case of NSCLC harboring concomitantEGFRG719C and S768I mutations who received afatinib rechallenge followed by chemotherapy. The present case suggests that combined therapeutic strategies such as afatinib plus sequential chemotherapy would be beneficial based on appropriately timed rebiopsies from recurrent lesions. Key pointsSignificant findings of the study and what this study adds A NSCLC patient carryingEGFRG719X/S768I mutations survived for a long period of time with afatinib rechallenge followed by chemotherapy. Combined therapeutic strategies should be considered based on rebiopsies in appropriate timing in NSCLC with uncommonEGFRmutations.